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Background: In contrast to blood, which has mechanisms to maintain a homeostatic internal environment, urine is
more likely to reflect changes in the body. As urine accumulates all types of changes, identifying the precise cause
of changes in the urine proteome is challenging and crucial in biomarker discovery. To reduce the effects of both
genetic and environmental factors on the urinary proteome, this study used a rat model of adriamycin-induced
nephropathy resembling human focal segmental glomerulosclerosis (FSGS) development.
Results: Urine samples were collected at before adriamycin administration and day3, 7, 11, 15 and 23 after. Urinary
proteins were profiled by liquid chromatography coupled with tandem mass spectrometry (LC-MS/MS). Of 23
changed proteins with disease development, 20 have human orthologs, and 13 proteins were identified as stable in
normal human urine, meaning that changes in these proteins are more likely to reflect disease. Fifteen of the
identified proteins have not been established to function in FSGS development. Seven proteins were selected for
verification in ten more rats as markers closely associated with disease severity by western blot.
Conclusion: We identified proteins changed in different stages of FSGS in rat models, which may aid in biomarker
development and the understanding of FSGS pathogenesis.
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Biomarkers represent measurable changes associated with
a physiological or pathophysiological process. In contrast
to the blood, which has mechanisms to maintain a ho-
meostatic internal environment, urine is more likely to
reflect changes in the body and can be collected noninva-
sively [1,2]. Due to the site of the formation and regulation
of urine, the urine proteome has been widely investigated
in studies of kidney, bladder and prostate diseases [3]. As
urine accumulates all types of changes, identifying the pre-
cise cause of changes in the urine proteome is challenging
and crucial in biomarker discovery. Using animal models
is the most efficient way to find the cause and effect
relationship, because of the following reasons. (1) Using
animal models can reduce the effects of genetic and envir-
onmental factors on the urine proteome as much as pos-
sible. (2) Exact starting of the disease is available, which is
helpful in the identification of biomarkers for each stages* Correspondence: gaoyouhe@pumc.edu.cn
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unless otherwise stated.including early detection. (3) It can avoid the effects of
medications on the urine proteome because therapeutic
measures for patients are inevitable.
With a significantly increasing frequency in the past
20 years, focal segmental glomerulosclerosis (FSGS) is
currently a common cause of nephrotic syndrome and re-
sponsible for 15% end-stage renal disease [4]. Some FSGS
patients require kidney transplantation, and approximately
one-fourth develop recurrent disease in the allograft [5].
The pathogenesis of FSGS remains unclear, and podocyte
effacement leading to the injury of the glomerular filtra-
tion barrier is considered a main characteristic. Protein-
uria is a leading clinical manifestation of this disease [6].
Only renal biopsy can distinguish different types of neph-
rotic syndrome. However, FSGS is “focal” and “segmental”,
so the diagnosis of FSGS is often more problematic and
complex [7]. Biomarkers in the urine are needed for its
early diagnosis and prognosis.
Adriamycin (ADR)-induced nephropathy is the most
prototypical and commonly used experimental model of
human primary FSGS [8]. Renal abnormalities induced
by ADR resembled FSGS in humans. The histologicaltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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by podocyte injury followed by glomerular sclerosis, tubu-
lointerstitial inflammation and fibrosis [9]. Analyzing the
urinary proteome at different stages and identifying candi-
date biomarkers related to disease development will lead
to a better understanding of FSGS pathogenesis.
In the late phase of FSGS, massive irreversible protein-
uria commonly occurs after podocyte injury, which in-
creases the difficulty of identifying some low-abundance
proteins by MS. Concanavalin A (ConA) enrichment is fre-
quently used to enrich for N-linked glycoproteins in both
plasma and urine proteomic studies [10,11]. As many exist-
ing biomarkers are glycoproteins, in this study, ConA-
enriched urinary protein was evaluated to monitor the
dynamic changes during FSGS development (Figure 1).
Results and discussion
The urinary protein to creatinine ratios increased
To monitor renal function, the urinary protein to creatin-
ine ratios were measured to determine the proteinuriaFigure 1 Workflow of protein identification in the FSGS rat
model. Urine was collected at days 0, 3, 7, 11, 15 and 23 after ADR
administration, and urinary proteins were enriched by ConA agarose
followed by liquid chromatography coupled with tandem mass
spectrometry (LC-MS/MS) identification. Several proteins were
verified in ten more rats by western blot analysis.levels. As shown in Figure 2A, the ratios increased. From
day 3 to day 7, the increase was moderate. Marked in-
creases occurred 11 days after ADR induction. To confirm
the successful induction of FSGS, the histological cha-
racteristics of the rat kidneys on days 23 and 50 were
examined. On day 23, the glomerular endothelium and
podocyte were partly effaced, foam cells were generated,
and fewer glomerular lesions with mesangial matrix ex-
pansion were present. On day 50, severe segmental and
global sclerosis, mesangial matrix expansion and intersti-
tial fibrosis were present (Figure 2B). All the features indi-
cated that the disease was in the late stage.
The urinary proteins at days 0, 3, 7, 11, 15 and 23 were
analyzed by SDS-PAGE. Compared with day 0, the ex-
pression of the 70-kD protein was gradually increased,
and this protein became the most intense band at day
23. The ConA-enriched samples at each stage were also
shown in Figure 2C.
Dynamic urinary proteome changes were identified by
LC-MS/MS
At the discovery stage, eighteen samples of three rats
(six time points each) were individually analyzed by UPLC
coupled with Triple-TOF 5600 MS. LC-MS Progenesis
software was used to calculate the normalized abundance
of each protein by measuring the peak area intensity. By
label-free quantitative and statistical analyses, 23 proteins
met the following criteria: (1) compared with day 0, fold
change > 2 in each rat and (2) p value < 0.05 (data were
analyzed by repeated measure ANOVA). Among the 23
changed proteins, 20 proteins were annotated as glycopro-
teins in the UniProt database, 12 proteins shared an over-
all increasing trend in relative abundance, and 9 proteins
shared an overall decreasing trend (Figure 3). The chan-
ged proteins are listed in Additional file 1 and the label-
free quantitation data are shown in Additional file 2.
Three trends were observed in these changed proteins
during ADR-induced nephropathy progression. The first
was a gradual increase, with examples including afamin
and ceruloplasmin. Urinary afamin increased only 1.16-
fold on the third day after ADR injection, remained ele-
vated compared with normal urine samples, and peaked
at 5.63-fold on day 23 after the ADR injection. The
second was a gradual decrease, with examples including
cadherin-2 and aggrecan core protein. Cadherin-2 de-
creased 1.1-fold after 3 days and continued to decrease
in the following days. The third, which includes fetuin-B
and beta-2-microglobulin, was early changes with dis-
tinct patterns. Fetuin-B decreased 2.39-fold on day 3 and
remained unchanged during the following days until in-
creasing 1.79-fold on day 23. Beta-2-microglobulin in-
creased 1.7-fold on day 3, decreased 2.83-fold on day 7,
and gradually increased 1.69-fold on day 23, compared
with the normal samples. The time-dependent changes
Figure 2 Dynamic changes in ADR-treated rats. A) Urinary protein to creatinine ratios in six phases of ADR treated rats. The data are expressed as
the mean ± standard deviation (n = 13, *p < 0.05 for Experiment vs. Control). The paired t test was used to assess the significance of the differences
between groups. B) Histological changes in ADR-treated rats (HE staining, 400×). Compared with the normal condition, on day 23, glomerular lesions
with mesangial matrix expansion could be detected; on day 50, glomerular sclerosis and severe interstitial expansion were found in many glomeruli.
C) Urinary protein and ConA-enriched urinary protein pattern of one FSGS model rat. Lane 1: Marker. Lanes 2–7, urinary proteins and ConA-enriched
urinary proteins at days 0, 3, 7, 11, 15 and 23 respectively.
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in Figure 3.
At the early stage, such as 3 and 7 days after the ADR
injection, proteinuria was not obvious. However, several
proteins, such as fetuin-B, AMBP and alpha-2-HS-glyco-
protein, were decreased during this phase. These proteins
may be good candidates for the early detection of FSGS.
Western blot validation
The urine samples from ten more rat models at six time
points each were collected for validation. Of 23 changed
proteins with disease development, nine altered pro-
teins (albumin, serotransferrin, alpha-1-antiproteinase,
afamin, ceruloplasmin, plasminogen, kininogen, alpha-
2-HS-glycoprotein and alpha 1 microglobulin [AMBP])
identified in our proteomic study with human orthologs at
relatively high abundance that also had commercially
available antibodies were selected to be analyzed by semi-
quantitative western blot analysis (Figure 4). Kininogen-1
and alpha-2-HS-glycoprotein were not detected by west-
ern blot. The changes in the other seven proteins were
consistent with the LC-MS/MS results.
Human orthologs of changed proteins
Changed proteins demonstrated in animal models are
more valuable if they can be confirmed in humans. Thechanged proteins were converted to their corresponding
human orthologs using Ensembl Gene ID(s) by Ensembl
BioMart (http://asia.ensembl.org/biomart/martview) as
described [12,13]. Of 23 identified changed proteins, 20
have human orthologs, including the seven validated by
western blot analysis.
Urinary proteins are mainly composed of plasma pro-
teins filtered by the glomerular barrier and proteins se-
creted from the kidney and urinary tract [14]. A previous
study compared the kidney input (plasma) and output
(urine) proteomes and divided urinary proteins into 3 cat-
egories, the plasma-only subproteome, the plasma-and-
urine subproteome, and the urine-only subproteome [15].
To further analyze the functions of these changed pro-
teins, they were compared with the human plasma prote-
ome, human urine proteome and kidney origin proteome.
The human proteome data were downloaded from the
Healthy Human Individual’s Integrated Plasma Proteome
[16], the human urine proteome data were acquired from
previous studies [17-19], and the kidney origin proteome
data were acquired from a kidney perfusion study [13].
The human orthologs of the changed proteins and their
relationships with the human plasma, urine and kidney
origin proteomes are shown in Table 1. Most changed
proteins exist in the normal human plasma proteome
(17/20) and urine proteome (18/20); however, the CD166
Figure 3 Expression of candidate urine biomarkers of ADR-induced nephropathy during six stages. A) Twelve proteins shared an overall
increasing trend in relative abundance. B) Nine proteins shared an overall decreasing trend. C) Two proteins changed at the early stage. The x
axis represents different stages; the y axis represents the normalized abundance identified by the LC-MS Progenesis software.
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kallikrein-1 was detected only in the normal urine prote-
ome, and 10 proteins were detected in the kidney origin
proteome. In addition, the urinary proteome is largely af-
fected by individual factors, but biomarkers should be ap-
plicable to most people, in other words, changes in the
stable contents of the healthy human urinary proteome
are more likely to be biomarkers [20]. A total of 560 pro-
teins were considered stable in healthy human urine [21].
Thirteen out of twenty changed proteins in this study
could be found among the stable proteins, indicating that
these changed proteins were more useful for clinical diag-
noses as they are not affected by individual differences
and are not time-dependent (Table 1).
Changed proteins identified by progressive ADR-induced
nephropathy were compared with a manually curated hu-
man and animal urinary protein biomarker database [34].
Five high-abundance urinary proteins, including albumin,
serotransferrin and kininogen-1, had been present inhigher levels in previous FSGS studies [22,24,26], which is
consistent with the results of this study. The other 15 pro-
teins were not found to be related to FSGS. Some proteins
were found to be candidate biomarkers for other glomeru-
lar diseases; for example, elevated afamin expression has
been reported in some diabetic nephropathies. The simi-
larities may due to a common pathway of different glom-
erular diseases at later stages [35]. Thus, these diseases
can be differentiated using changed proteins, especially
those significantly decreased proteins in the early stage,
such as fetuin-B and AMBP. Some candidates also ap-
peared in other renal diseases, whereas the opposite
trends were observed in different diseases. For exam-
ple, complement factor D and beta-2-glycoprotein 1
were higher in Fanconi syndrome [36] but lower in ADR-
induced nephropathy.
As shown in Table 1, the same urinary proteins appeared
to be modulated in several renal diseases. For example, al-
bumin was increased in both diabetic nephropathy and
Figure 4 Semi-quantitative western blot analysis of seven proteins. Semi-quantitation of albumin, serotransferrin, alpha-1-antiproteinase,
afamin, ceruloplasmin, plasminogen and AMBP determined by western blot analysis from ten additional rats at six time points each. The two
western blots for each protein shown are representative of the group of ten.
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accurate diagnosis using a single biomarker; a panel of
urinary proteins may be more specific and more sensitive.
In this study, the 20 proteins that have human orthologs
could be evaluated together to reflect the progression of
FSGS. We hope this work will help to support the role of
urine as a key source in biomarker discovery especially in
kidney diseases and help to identify FSGS biomarkers for
clinical utility.
As urine proteome is subjected to many factors like
diet, drugs and lifestyles, increasing the number of clin-
ical samples is laborious and almost futile with current
sample analysis throughput. We think finding clues from
well controlled animal experiment and validating them
in clinical samples is a better way to develop biomarkers
in urine [37]. The advantage of ConA enrichment in this
study is not as significant as we expected, but it did
not change the main idea of the paper. If these high
abundant protein panels identified in this study are
not sufficiently specific and sensitive to distinguish re-
nal diseases clinically, the identification of less abun-
dant proteins in the discovery phase will be necessary
in future studies.Conclusions
In this study, we set to observe the urine proteome
changes in rat models as the disease progress, which
may present a possible direction to break through the
current stalemate in urinary biomarker field. The results
showed proteins changed in different stages of FSGS,
which may aid in biomarker development and the un-
derstanding of FSGS pathogenesis.
Methods
Experimental animals
Rats were purchased from the Institute of Laboratory
Animal Science, Chinese Academy of Medical Science &
Peking Union Medical College. The experiment was ap-
proved by Institute of Basic Medical Sciences Animal
Ethics Committee, Peking Union Medical College. All
animals were maintained with a standard laboratory diet
under controlled indoor temperature (22 ± 1°C) and hu-
midity (65 – 70%) conditions. The study was performed
strictly according to the guidelines developed by the
Institutional Animal Care and Use Committee of Peking
Union Medical College. All efforts were made to minimize
suffering.











Candidate biomarkers of diseases
P01009 Alpha-1-antiproteinase Yes Yes Yes Yes FSGS [22]
P43652 Afamin Yes Yes Yes Yes Diabetic nephropathy [23]
P02768 Serum albumin Yes Yes Yes Yes Adriamycin nephropathy mice model [24]
P00450 Ceruloplasmin Yes Yes Yes Yes Diabetic nephropathy [25]
P01042 Kininogen-1 Yes Yes Yes Yes Adriamycin nephropathy rat model [26]
P02787 Serotransferrin Yes Yes Yes Yes Adriamycin nephropathy mice model [24]
P23141 Carboxylesterase 1 Yes Yes No No None
P01861 Ig gamma-4 chain C region Yes Yes No No Kidney calculi [27]
P00747 Plasminogen Yes Yes No Yes Acute appendicitis [28]
P02765 Alpha-2-HS-glycoprotein Yes Yes Yes Yes Diabetic nephropathy [23]
P02760 Protein AMBP Yes Yes Yes Yes FSGS [22]
Q96D42 T-cell immunoglobulin and mucin
domain-containing protein 1
No No No No Renal cell carcinoma [29], acute renal
failure [30]
P19022 Cadherin-2 Yes Yes No Yes Ureteropelvic junction obstruction [31]
Q6PID9 Aggrecan core protein No Yes No No None
P00746 Complement factor D Yes Yes No No Dents disease [32]
P02749 Beta-2-glycoprotein 1 Yes Yes No Yes Dents disease [32]
Q13740 CD166 antigen Yes No No No None
P06870 Kallikrein-1 No Yes No Yes None
P61769 Beta-2-microglobulin Yes Yes Yes Yes Renal Interstitial Inflammation [33]
Q9UGM5 Fetuin-B Yes Yes Yes No None
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Young Sprague–Dawley male rats (n = 13, initial weight
200 g) were given a single intravenous injection of ADR
(5 mg/kg). Urine samples were collected at days 0 (be-
fore injection), 3, 7, 11, 15 and 23 after the rats were
placed in metabolic cages 4 hours individually. During
urine collection, to avoid contamination, all rats were
given free access to water but no food. After sample col-
lection, six rats were sacrificed on day 23, and the re-
mainder were sacrificed on day 50. The 13 harvested
kidneys were subjected to histopathological examination.
The urinary proteins to creatinine ratio was evaluated to
determine the proteinuria level [38]. The self-controlled
experiment was conducted in two phases: for the dis-
covery phase, differential protein identification was per-
formed in three independent rats; for the validation phase,
samples were obtained from the ten remaining rats, with
each animal providing six urine samples.
ConA enrichment of urinary proteins
Once collected, the urine was centrifuged at 2000 g for
15 min. After removing the cell debris, the supernatant
was centrifuged at 12 000 g for 15 min at 4°C. Urinary
proteins were extracted by acetone precipitation from
the individual urine samples. Then, 25 mM NH4HCO3
was used to re-dissolve the pellets after centrifugation at12 000 g. The protein concentration of each sample was
measured by the Bradford method.
The enrichment of ConA-binding urinary proteins was
conducted in the three rats that were used in the prote-
omic analysis, as described previously [39]. The individ-
ual samples from each time point were incubated with
ConA agarose at 4°C overnight. To remove non-specific
ConA-binding proteins, the sample-loaded beads were
washed with Buffer A (150 mM NaCl, 1 mM CaCl2,
1 mM MgCl2, 20 mM Tris, pH 7.4) three times. The
target proteins were eluted with 500 mM methyl α-D-
glucopyranoside in buffer A.
To examine the differences between urinary proteins
and ConA-enriched proteins, SDS-PAGE was used to
separate the proteins. 20 μg of urinary proteins at dif-
ferent stages of FSGS and 5 μg of their corresponding
ConA-enriched proteins were loaded onto 20*12-cm
12% SDS-PAGE. The gels were stained with Coomassie
Brilliant Blue.
Tryptic digestion
The proteins were digested with trypsin (Trypsin Gold,
Mass Spec Grade, Promega, Fitchburg, WI) using filter-
aided sample preparation methods [40]. After 100 μg of
ConA-enriched proteins were loaded on the 10-kD filter
devices (Pall, Port Washington, New York, USA), 200 μl
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twice to wash the proteins, and the tube was centrifuged
at 14 000 g for 20 min at 18°C. The proteins were dena-
tured by incubating with 5 mM dithiothreitol (DTT) at
50°C for 1 h and then alkylated in the dark for 45 min
by the addition of 50 mM iodoacetamide (IAA). The
resulting proteins were diluted in 300 μl of UA and
centrifuged twice. The concentrate was redissolved in
50 mM NH4HCO3. Then, trypsin was added (enzyme
to protein ratio of 1:50) and incubated at 37°C over-
night. The digested peptides were collected by centri-
fugation and sequential incubation with PNGase F (New
England Biolabs, USA) overnight. The filtrates were de-
salted using Oasis HLB cartridges (Waters, Milford, MA)
and then dried by vacuum evaporation (Thermo Fisher
Scientific, Bremen, Germany).LC-MS/MS analysis
The digested peptides were dissolved in 0.1% formic acid
and transferred to a reversed-phase microcapillary col-
umn using a Waters UPLC system. The peptides were
separated on a 10-cm fused silica column. Elution was
performed over a gradient of 5%–28% buffer B (0.1% for-
mic acid, 99.9% ACN; flow rate, 0.3 μL/min). The MS
data were acquired using the AB SCIEX (Framingham,
MA, US) Triple-TOF 5600 mass spectrometer system.
Three biological replicates were performed in this study,
with each having six samples.Protein identification and label-free quantitation
The MS/MS data were processed using Mascot software
(version 2.4.1, Matrix Science, London, UK) and searched
against the Swissprot_2013_05 database (taxonomy:
Rattus; containing 9,354 sequences). For peptide iden-
tification, the fragment ion mass tolerance was set to
0.05 Da, and the parent ion tolerance was set to 0.05 Da.
The search allowed two missed cleavage sites in the tryp-
sin digestion. The carbamidomethylation of cysteines was
considered a fixed modification, and the oxidation of me-
thionine and deamidation of asparagine were considered
variable modifications. Peptide and protein identifications
were validated by Scaffold (version 4.0.1, Proteome Soft-
ware Inc., Portland, OR). Peptide identifications were ac-
cepted if they could be established to achieve an FDR less
than 1%. Protein identifications were accepted if they
could be established at greater than 95.0% probability. The
label-free quantification was conducted as previously
described [41] using Progenesis LC-MS/MS software
(version 4.1, Nonlinear, Newcastle upon Tyne, UK). Briefly,
the acquired data of the MS scans were transformed and
stored in peak lists using a proprietary algorithm. Features
with only one charge or more than five charges were ex-
cluded from the analyses. Protein abundance is calculatedfrom the sum of all unique peptide ion abundances for a
specific protein on each run. Normalisation of abundance
is required to allow comparisons across different sample
runs by this software. For further quantitation, all peptides
(with Mascot score > 20 and p < 0.01) of an identified pro-
tein were included. Proteins identified by more than one
peptide were retained.Western blot verification
A total of 20 μg of urinary proteins from individual sam-
ples (n = 10, six samples per rat) were loaded on 10%
SDS-PAGE and transferred to PVDF membranes. After
blocking in 5% (w/v) skim milk for 1 h at room tem-
perature, the membranes were incubated with the pri-
mary antibodies overnight at 4°C. The antibodies used
for the analysis included albumin (anti-albumin, 1:1000,
ab106582, Abcam, Cambridge, U.K.), serotransferrin (anti-
serotransferrin, 1:10000, ab82411, Abcam, Cambridge,
U.K.), alpha-1-antiproteinase (anti-alpha-1-antiproteinase,
1:10000, ab106582, Abcam, Cambridge, U.K.), afamin
(anti-afamin, 1:300, sc-74311, Santa Cruz Biotechnology,
Santa Cruz, CA), ceruloplasmin (anti-ceruloplasmin,
1:1000, ab131220, Abcam, Cambridge, U.K.), plasminogen
(anti-plasminogen, 1:10000, ab6189, Abcam, Cambridge,
U.K.), T-kininogen 1 (anti- kininogen 1, 1:300, sc-103886,
Santa Cruz Biotechnology, Santa Cruz, CA), alpha-2-HS-
glycoprotein (alpha-2-HS-glycoprotein antibody, 1:300,
sc-20872, Santa Cruz Biotechnology, Santa Cruz, CA) and
AMBP (anti-alpha 1 microglobulin, 1:1000, ab110707,
Abcam, Cambridge, U.K.). The membranes were then
washed with TBST three times and incubated with hor-
seradish peroxidase-conjugated secondary antibody. Im-
munoreactive proteins were visualized using enhanced
chemiluminescence (ECL) reagents. ECL results were
scanned and analyzed using an ImageQuant 400TM
Imager (GE Healthcare Life Sciences, Piscataway, New
Jersey, USA) and the intensity of each protein band
was quantified using Image J analysis software (National
Institutes of Health, Bethesda, Maryland, USA).Additional files
Additional file 1: The changed proteins identified in all samples.
Additional file 2: The label-free quantitation data of proteins
identified in each sample.Competing interests
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